G-CSF in the Prevention of Febrile Neutropenia in Chemotherapy in Breast Cancer Patients

Publisher： Karger

E-ISSN： 2296-5262|29|4|171-178

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.29, Iss.4, 2006-03, pp. : 171-178

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin’s Lymphoma

By  

Oncology Research and Treatment, Vol. 32, Iss. 10, 2009-09 ,pp. : 599-604

Karger

Access to resources Recommend Favorite

Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea

By  

Oncology, Vol. 91, Iss. 5, 2016-09 ,pp. : 274-282

Karger

Access to resources Recommend Favorite

Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy

By Tan Sean P.   Chouaid C.   Hettler D.   Baud M.   Hejblum G.   Tilleul P.  

Current Medical Research and Opinion, Vol. 25, Iss. 6, 2009-06 ,pp. : 1455-1460

Informa Healthcare

Access to resources Recommend Favorite

The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin‐6 and C‐reactive protein by modelling

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 84, Iss. 3, 2018-03 ,pp. : 490-500

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Outcomes and Cost‐effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer

By  

THE BREAST JOURNAL, Vol. 21, Iss. 6, 2015-11 ,pp. : 658-664

John Wiley & Sons Inc

Access to resources Recommend Favorite